Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Masaru Matsuda Sells 1,230 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Masaru Matsuda sold 1,230 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $32,127.60. Following the completion of the sale, the insider owned 126,171 shares in the company, valued at approximately $3,295,586.52. This trade represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arcutis Biotherapeutics Price Performance

Shares of ARQT opened at $27.10 on Thursday. The firm has a 50-day simple moving average of $25.87 and a two-hundred day simple moving average of $24.68. The stock has a market cap of $3.39 billion, a PE ratio of -903.03 and a beta of 1.49. Arcutis Biotherapeutics, Inc. has a 1-year low of $13.69 and a 1-year high of $31.77. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.68 and a quick ratio of 2.46.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.06 by $0.05. Arcutis Biotherapeutics had a negative return on equity of 1.41% and a negative net margin of 0.57%.The business had revenue of $129.86 million during the quarter, compared to analyst estimates of $118.85 million. As a group, analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.16 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Wall Street Zen upgraded Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Wednesday, June 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $36.00 price target on shares of Arcutis Biotherapeutics in a report on Thursday, May 7th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Arcutis Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.00.

Key Headlines Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong revenue growth and earnings beat: Second-quarter net product revenue reached $129.9 million, up 59% from the prior-year quarter and 23% sequentially. Adjusted earnings of $0.11 per share exceeded analyst estimates ranging from $0.06 to $0.09, compared with a $0.13 loss a year earlier. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Raised 2026 sales outlook: Arcutis increased its full-year net product sales guidance to $525 million–$540 million, signaling confidence in sustained demand for ZORYVE. The company also maintained positive operating cash flow during the quarter. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Expanded growth opportunities: The FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as two. The FDA also accepted an application for use in infants aged three to 24 months with mild-to-moderate atopic dermatitis, with a target decision date of February 23, 2027. Enrollment is complete in a Phase 2 vitiligo study, with results expected in the fourth quarter of 2026. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Insider sales appear administrative: Three executives sold a combined 6,560 shares at approximately $26.12 per share. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, limiting their significance as a bearish signal. SEC Insider Trading Filing

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. lifted its position in shares of Arcutis Biotherapeutics by 325.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after purchasing an additional 833 shares during the last quarter. Global Retirement Partners LLC purchased a new position in Arcutis Biotherapeutics in the fourth quarter valued at $35,000. EverSource Wealth Advisors LLC raised its stake in Arcutis Biotherapeutics by 124.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after buying an additional 698 shares in the last quarter. NewEdge Advisors LLC raised its stake in Arcutis Biotherapeutics by 209.0% in the fourth quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock valued at $45,000 after buying an additional 1,045 shares in the last quarter. Finally, Truvestments Capital LLC lifted its holdings in Arcutis Biotherapeutics by 114.2% during the 4th quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock worth $87,000 after buying an additional 1,606 shares during the last quarter.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.